Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Piera Gargiulo
Observed names:
Gargiulo Piera,
Gargiulo, Piera,
P Gargiulo,
P. Gargiulo
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institutions:
Federico II University Hospital,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Swiss Group For Clinical Cancer Research,
Ospedale D. Cotugno,
University of Naples Federico II
ORCID:
0000-0002-8828-4209
Observed ORCID:
0000-0002-8828-4209
OpenAlex ID:
A5001464256
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
2020
·
Francesco Perrone
, Maria Carmela Piccirillo
, et al.
·
Journal of Translational Medicine
·
149
PDF
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
2023
·
Quincy Chu
, Francesco Perrone
, et al.
·
The Lancet
·
139
Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
2016
·
Piera Gargiulo
, Chiara Della Pepa
, et al.
·
Cancer Treatment Reviews
·
130
Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy
2014
·
Chiara Della Pepa
, Giuseppe Tonini
, et al.
·
Cancer Treatment Reviews
·
110
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
2022
·
Antonio González-Martín
, Christophe Desauw
, et al.
·
European Journal of Cancer
·
91
PDF
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
2022
·
Maria Carmela Piccirillo
, Laura Bonanno
, et al.
·
Journal of Thoracic Oncology
·
73
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
2016
·
Marta Bonotto
, Lorenzo Gerratana
, et al.
·
The Breast
·
67
PDF
Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis
2016
·
Piera Gargiulo
, Matilde Pensabene
, et al.
·
BMC Cancer
·
46
PDF
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin
2016
·
A. Bergamini
, C. Pisano
, et al.
·
Gynecologic Oncology
·
41
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023
·
Raphaël Leman
, Etienne Muller
, et al.
·
Clinical Cancer Research
·
37
PDF
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
2017
·
A. Stathis
, D. Hess
, et al.
·
Investigational New Drugs
·
34
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study
2023
·
Laura Marandino
, Federica Trastu
, et al.
·
BMJ Oncology
·
32
PDF
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study
2023
·
Alessandro Rossi
, Giacomo Aimar
, et al.
·
European Journal of Cancer
·
31
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
2021
·
Piera Gargiulo
, Laura Arenare
, et al.
·
BMC Cancer
·
31
PDF
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
2023
·
Maria Carmela Piccirillo
, Quincy Chu
, et al.
·
Journal of Thoracic Oncology
·
26
PDF
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study
2021
·
Daniela Califano
, Daniela Gallo
, et al.
·
Cancers
·
25
PDF
Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer
2015
·
Piera Gargiulo
, Laura Arenare
, et al.
·
Oncology
·
25
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials
2024
·
L. Arenare
, R. Di Liello
, et al.
·
ESMO Open
·
20
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
2019
·
Piera Gargiulo
, Daniel Dietrich
, et al.
·
Therapeutic Advances in Medical Oncology
·
18
PDF
1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial
2021
·
M.C. Piccirillo
, L. Bonanno
, et al.
·
Annals of Oncology
·
15
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
2020
·
Daniela Califano
, Daniela Russo
, et al.
·
Cells
·
15
PDF
Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials
2021
·
Raimondo Di Liello
, Maria Carmela Piccirillo
, et al.
·
Life
·
14
PDF
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients
2022
·
Crescenzo D’Alterio
, Anna Spina
, et al.
·
Cancers
·
13
PDF
LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial
2020
·
A. González Martín
, Y. Tazi
, et al.
·
Annals of Oncology
·
13
PDF
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
2019
·
Alessandra Curioni-Fontecedro
, Jean Yannis Perentes
, et al.
·
British Journal of Cancer
·
12
PDF
Show more works
View as search
Works count:
85
Citation count:
1,417
H-index:
19
I10-index:
26
Year
Topic
Type